Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk

Circulation Research

Volumn 118, Issue 7, 2016, Pages 1106-1115

  Lawler, Patrick R ^a,b,c   Akinkuolie, Akintunde O ^a   Chandler, Paulette D ^a   Moorthy, M Vinayaga ^a   Vandenburgh, Martin J ^a   Schaumberg, Debra A ^a,d   Lee, I Min ^a,c   Glynn, Robert J ^a,c   Ridker, Paul M ^a,b,c   Buring, Julie E ^a,c   Mora, Samia ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular diseases; glycoproteins; magnetic resonance spectroscopy; metabolomics; mortality; neoplasms; risk factors

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACETYLSALICYLIC ACID; ACUTE PHASE PROTEIN; ALPHA TOCOPHEROL; BETA CAROTENE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N ACETYLGLUCOSAMINE; PHOSPHOLIPASE A2; PLACEBO; ROSUVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 2; UNCLASSIFIED DRUG; GLYCOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; N ACETYLGALACTOSAMINE; PLASMA PROTEIN; POLYSACCHARIDE;

ADULT; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COLORECTAL CANCER; FOLLOW UP; HUMAN; INFLAMMATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASM; MIDDLE AGED; MORTALITY RISK; OUTCOME ASSESSMENT; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIACYLGLYCEROL BLOOD LEVEL; WOMEN'S HEALTH; AGED; BLOOD; CAUSE OF DEATH; CHEMISTRY; COMPARATIVE STUDY; FEMALE; KAPLAN MEIER METHOD; MALE; MORTALITY; NEOPLASM; NUCLEAR MAGNETIC RESONANCE; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK;

ACETYLGALACTOSAMINE; ACETYLGLUCOSAMINE; ACUTE-PHASE PROTEINS; AGED; BIOMARKERS; BLOOD PROTEINS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; KAPLAN-MEIER ESTIMATE; LIPIDS; MALE; MIDDLE AGED; MORTALITY; NEOPLASMS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; POLYSACCHARIDES; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK;

EID: 84961226679     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.308078     Document Type: Article

References (30)

1. Hebert DN, Lamriben L, Powers ET, Kelly JW, The intrinsic and extrinsic effects of N-linked glycans on glycoproteostasis. Nat Chem Biol 2014 10 902 910. doi: 10.1038/nchembio.1651
2. Shrimal S, Cherepanova NA, Gilmore R, Cotranslational and posttranslocational N-glycosylation of proteins in the endoplasmic reticulum. Semin Cell Dev Biol 2015 41 71 78. doi: 10.1016/j.semcdb.2014.11.005
3. Sperandio M, Gleissner CA, Ley K, Glycosylation in immune cell trafficking. Immunol Rev 2009 230 97 113. doi: 10.1111/j.1600-065X.2009.00795.x
4. Arnold JN, Saldova R, Hamid UM, Rudd PM, Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics 2008 8 3284 3293. doi: 10.1002/pmic.200800163
5. Ohtsubo K, Marth JD, Glycosylation in cellular mechanisms of health and disease. Cell 2006 126 855 867. doi: 10.1016/j.cell.2006.08.019
6. Hart GW, Copeland RJ, Glycomics hits the big time. Cell 2010 143 672 676. doi: 10.1016/j.cell.2010.11.008
7. Gornik O, Lauc G, Glycosylation of serum proteins in inflammatory diseases. Dis Markers 2008 25 267 278
8. Akinkuolie AO, Pradhan AD, Buring JE, Ridker PM, Mora S, Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2015 35 1544 1550. doi: 10.1161/ATVBAHA.115.305635
9. Akinkuolie AO, Buring JE, Ridker PM, Mora S, A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc 2014 3 e001221. doi: 10.1161/JAHA.114.001221
10. Otvos JD, Shalaurova I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH, Tracy RP, GlycA: A Composite Nuclear Magnetic Resonance Biomarker of Systemic Inflammation. Clin Chem 2015 61 714 723. doi: 10.1373/clinchem.2014.232918
11. Ala-Korpela M, Serum nuclear magnetic resonance spectroscopy: one more step toward clinical utility. Clin Chem 2015 61 681 683. doi: 10.1373/clinchem.2015.238279
12. Bell JD, Brown JC, Nicholson JK, Sadler PJ, Assignment of resonances for 'acute-phase' glycoproteins in high resolution proton NMR spectra of human blood plasma. FEBS Lett 1987 215 311 315
13. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE, A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005 352 1293 1304. doi: 10.1056/NEJMoa050613
14. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE, Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005 294 47 55. doi: 10.1001/jama.294.1.47
15. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE, Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005 294 56 65. doi: 10.1001/jama.294.1.56
16. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE, Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013 159 77 85. doi: 10.7326/0003-4819-159-2-201307160-00002
17. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR, Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002 347 1557 1565. doi: 10.1056/NEJMoa021993
18. Mora S, Rifai N, Buring JE, Ridker PM, Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem 2009 55 888 894. doi: 10.1373/clinchem.2008.117929
19. Mora S, Lee IM, Buring JE, Ridker PM, Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA 2006 295 1412 1419. doi: 10.1001/jama.295.12.1412
20. 2 mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial. Clin Chem 2012 58 877 886. doi: 10.1373/clinchem.2011.180281
21. Sesso HD, Gaziano JM, Glynn RJ, Buring JE, Value of an Endpoints Committee versus the use of nosologists for validating cause of death. Contemp Clin Trials 2006 27 333 339. doi: 10.1016/j.cct.2005.11.007
22. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 359 2195 2207. doi: 10.1056/NEJMoa0807646
23. Tousoulis D, Psarros C, Demosthenous M, Patel R, Antoniades C, Stefanadis C, Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol 2014 63 2491 2502. doi: 10.1016/j.jacc.2014.01.054
24. Ngoh GA, Facundo HT, Zafir A, Jones SP, O-GlcNAc signaling in the cardiovascular system. Circ Res 2010 107 171 185. doi: 10.1161/CIRCRESAHA.110.224675
25. Pu Q, Yu C, Glycosyltransferases, glycosylation and atherosclerosis. Glycoconj J 2014 31 605 611. doi: 10.1007/s10719-014-9560-8
26. An HJ, Lebrilla CB, A glycomics approach to the discovery of potential cancer biomarkers. Methods Mol Biol 2010 600 199 213. doi: 10.1007/978-1-60761-454-8-14
27. Brenner DR, Scherer D, Muir K, Schildkraut J, Boffetta P, Spitz MR, Le Marchand L, Chan AT, Goode EL, Ulrich CM, Hung RJ, A review of the application of inflammatory biomarkers in epidemiologic cancer research. Cancer Epidemiol Biomarkers Prev 2014 23 1729 1751. doi: 10.1158/1055-9965.EPI-14-0064
28. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J, Emerging Risk Factors Collaboration C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010 375 132 140. doi: 10.1016/S0140-6736(09)61717-7
29. Ramos-Nino ME, The role of chronic inflammation in obesity-associated cancers. ISRN Oncol 2013 2013 697521. doi: 10.1155/2013/697521
30. Fischer K, Kettunen J, Würtz P, Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: an observational study of 17,345 persons. PLoS Med 2014 11 e1001606. doi: 10.1371/journal.pmed.1001606